Key Highlights

  • Cash, equivalents and marketable securities came to USD 61.4 million at June 30, 2026, and management expects that to last into 2027.
  • The second quarter 2026 net loss narrowed to USD 1.7 million from USD 6.4 million a year earlier, which equals USD 0.06 per share compared with USD 0.52.
  • Other income of USD 8.4 million in the second quarter of 2026 mostly reflected a change in the Fair Value of Warrant liability.
  • Two complete response letters, from June 2025 and June 2026, flagged the same third-party Manufacturing shortfalls for oxylanthanum carbonate and raised no efficacy or safety questions.

Pre-Report Setting for Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on November 16, 2026

Unicycive Therapeutics (NASDAQ:UNCY) is set to release third quarter 2026 figures on Monday, November 16, 2026, covering the quarter that ended September 30, 2026. With no product Revenue so far, the clinical-stage company will draw attention to operating spend, cash on hand and regulatory progress instead. The year-earlier quarter, the third quarter of 2025, showed USD 42.7 million of cash and a loss of USD 0.13 per share. In the second quarter of 2026 the per-share loss was USD 0.06, with the net loss at USD 1,722 thousand, compared with USD 6,447 thousand twelve months earlier.

Rising Costs and the Manufacturing Inspection Path at Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Research and development expense at Unicycive Therapeutics (NASDAQ:UNCY) rose to USD 2.8 million from USD 1.8 million. General and administrative costs moved up to USD 7.4 million from USD 5.2 million, and combined Operating Expense works out to USD 10.2 million on a calculated basis. Management traced the jumps to non-cash stock-based compensation, which rose USD 0.9 million and USD 1.4 million in those lines respectively, along with USD 0.4 million for commercial launch preparations. For Unicycive Therapeutics, Inc. (NASDAQ:UNCY), the FDA has assigned a Facility inspection to its third-party manufacturer. Chief Executive Officer Shalabh Gupta called the assignment a positive step and said the company expects to resubmit its new drug application once that facility passes inspection.

Liquidity Against Operating Costs and Risks at Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) held USD 61.4 million of Liquidity at June 30, 2026, against a calculated quarterly operating expense of USD 10.2 million, which supports the stated runway into 2027. Non-cash warrant fair value gains narrowed the reported net loss, so quarterly results can swing with the share price. No PDUFA date has been disclosed by Unicycive Therapeutics, Inc. (NASDAQ:UNCY). Key concerns: reliance on a lone outside manufacturer, how the FDA inspection turns out, possible further regulatory setbacks, the need to raise more money, and whether the launch in dialysis patients succeeds commercially.

Where Things Stand

Heading into a November 16, 2026 print, Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has its lead program parked behind a facility inspection rather than fresh clinical readouts. The USD 1.7 million second quarter net loss appears modest, but it includes USD 8.4 million of other income, while USD 10.2 million of operating expense shows the underlying cost base as launch preparation builds. Liquidity of USD 61.4 million, with a runway stretching into 2027, buys management time to finish the inspection and refile for oxylanthanum carbonate. The third-quarter update is expected to refresh the inspection timeline, spending trend and any change to the resubmission plan for chronic kidney disease patients on dialysis.